Clinical trial
Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and…
NCT00150748 · UCB Pharma SA, Industry · Completed
Key facts
| NCT number | NCT00150748 |
|---|---|
| Title | Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized Epilepsy |
| Official title | An Open-label, Multicenter, Follow-up Study to Evaluate the Safety and Efficacy of Levetiracetam (LEV) (Oral Tablets of 166, 250 or 500 mg b.i.d.), at Individualized Doses up to a Maximum of 4000 mg/Day (or 80 mg/kg/Day for Children and Adolescents Less Than 50 kg), in Children (≥ 4 Years Old)… |
| Lead sponsor | UCB Pharma SA, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Generalized Epilepsy |
| Intervention type | Drug |
| Interventions | Levetiracetam 166 mg, Levetiracetam 250 mg, Levetiracetam 500 mg |
| Enrollment | 217 |
| Start date | Nov 1, 2001 |
| Primary completion | Jul 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | Sep 8, 2005 |
| Last update posted | Jul 29, 2020 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: